M
Marie Marchand
Researcher at Ludwig Institute for Cancer Research
Publications - 27
Citations - 2782
Marie Marchand is an academic researcher from Ludwig Institute for Cancer Research. The author has contributed to research in topics: Antigen & CTL*. The author has an hindex of 18, co-authored 27 publications receiving 2750 citations. Previous affiliations of Marie Marchand include Cliniques Universitaires Saint-Luc & Université catholique de Louvain.
Papers
More filters
Journal ArticleDOI
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
Marie Marchand,N van Baren,N van Baren,P. Weynants,P. Weynants,Vincent Brichard,Vincent Brichard,Vincent Brichard,Brigitte Dreno,M H Tessier,E Rankin,Giorgio Parmiani,Flavio Arienti,Yves Humblet,A Bourlond,Romain Vanwijck,Danielle Lienard,Marc Beauduin,Pierre-Yves Dietrich,Vincenzo Russo,Joseph Kerger,Giuseppe Masucci,Elke Jäger,J. P. De Greve,J Atzpodien,Francis Brasseur,Francis Brasseur,Pierre Coulie,P. van der Bruggen,P. van der Bruggen,Thierry Boon,Thierry Boon +31 more
TL;DR: The results suggest that injection of the MAGE‐3.A1 peptide induced tumor regression in a significant number of the patients, even though no massive CTL response was produced.
Journal ArticleDOI
Expression of MAGE genes in primary and metastatic cutaneous melanoma.
Francis Brasseur,Donata Rimoldi,Danielle Lienard,Danielle Lienard,Bernard Lethe,Stefan Carrel,Flavio Arienti,Ludwig Suter,Romain Vanwijck,André Bourlond,Yves Humblet,Angelo Vacca,Marina Conese,Thierry Lahaye,Gérard Degiovanni,Rika Deraemaecker,Marc Beauduin,Xavier Sastre,Emile Salamon,Brigitte Dreno,Elke Jäger,Alexander Knuth,Christine Chevreau,Stefan Suciu,Jean-Marie Lachapelle,Pierre Pouillart,Giorgio Parmiani,Ferdy Lejeune,Jean-Charles Cerottini,Thierry Boon,Marie Marchand +30 more
TL;DR: MAGE expression in primary tumors was correlated with tumor thickness: there was a significantly increased frequency in the expression of MAGE‐1, ‐2 and ‐3 in tumors of greater thickness.
Journal ArticleDOI
A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3
Pierre Coulie,Vaios Karanikas,Didier Colau,Christophe Lurquin,Claire Landry,Marie Marchand,Thierry Dorval,Vincent Brichard,Thierry Boon +8 more
TL;DR: The results prove unambiguously that vaccines containing only a tumor-specific antigenic peptide can elicit a CTL response, and suggest that low-level CTL responses can initiate tumor rejection.
Journal ArticleDOI
Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection.
Frederic Lehmann,Marie Marchand,Philippe Hainaut,Pierre Pouillart,Xavier Sastre,Hideyuki Ikeda,Thierry Boon,Pierre Coulie +7 more
TL;DR: The results suggest that in patient LB33 the melanoma cells may have lost the expression of several HLA molecules under the selective pressure of an anti‐tumor CTL response.
Journal ArticleDOI
Tumoral and Immunologic Response After Vaccination of Melanoma Patients With an ALVAC Virus Encoding MAGE Antigens Recognized by T Cells
Nicolas van Baren,Marie-Claude Bonnet,Brigitte Dréno,Amir Khammari,Thierry Dorval,Sophie Piperno-Neumann,Danielle Liénard,Daniel E. Speiser,Marie Marchand,Vincent Brichard,Bernard Escudier,Sylvie Negrier,Pierre-Yves Dietrich,Dominique Maraninchi,Susanne Osanto,Ralf G. Meyer,Gerd Ritter,Philippe Moingeon,Jim Tartaglia,Pierre van der Bruggen,Pierre Coulie,Thierry Boon +21 more
TL;DR: Repeated vaccination with ALVAC miniMAGE-1/3 is associated with tumor regression and with a detectable CTL response in a minority of melanoma patients, and there is a significant correlation between tumor regressions and C TL response.